# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...
HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...
Barclays analyst Carter Gould maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...
Piper Sandler analyst Allison Bratzel maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price targe...
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from ...
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of ...